Evidence generation

Schedule a call

How can we help?

Designed to meet the requirements of the most demanding payers, all evidence generation projects are appropriate to each scope market.

Meeting
payer requirements

From analysis of eligible patient populations and patient preference and utility studies to ITC/NMA feasibility assessments, our evidence generation projects are tailored to your asset and to meet the requirements of the most challenging payers.

From analysis of eligible patient populations and patient preference and utility studies to ITC/NMA feasibility assessments, our evidence generation projects are tailored to your asset and to meet the requirements of the most challenging payers.

Access to over
2,000 advisors globally

Generate and validate supporting evidence for your asset with access to our international network of expert advisors. You will gain unique insights on challenges and policy stance across major markets that are tailored to your needs.

Generate and validate supporting evidence for your asset with access to our international network of expert advisors. You will gain unique insights on challenges and policy stance across major markets that are tailored to your needs.

The right study for your market access needs

Through close collaboration and asking pertinent questions that help define your needs, we create pragmatic solutions tailored to your specific challenges. And if your focus changes mid-project, we’ll change with you.

Through close collaboration and asking pertinent questions that help define your needs, we create pragmatic solutions tailored to your specific challenges. And if your focus changes mid-project, we’ll change with you.

Speechless! The results are truly impressive and exceed our expectations. This consummate piece of work provides a comprehensive analysis for our current position and an elevated vision for our future plan.

Global Market Access Partner, top-5 pharmaceutical company

Case studies

Find out how we partner with clients to enable faster patient access to therapies that improve health outcomes.

Healthcheck assessment for novel asset in moderate to severe rheumatoid arthritis

Market access roadmap in hemophilia B

Accelerate the generation of simultaneous HTA submissions

Publications

Case studies

Webinars

News

You have a vision; we are the consulting partner that will get you there.

We would be delighted to have a confidential conversation about your market access needs.